NeuroMetrix (NURO) 10-K 24 Feb 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 03, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'NURO	'	'
Entity Common Stock, Shares Outstanding	'	5,945,581	'
Entity Registrant Name	'NeuroMetrix, Inc.	'	'
Entity Central Index Key	'0001289850	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$4,743,950
Current Fiscal Year End Date	'--12-31	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$9,195,753	$8,699,478
Accounts receivable, net of allowances of $35,895 and $151,616 at December 31, 2013 and 2012, respectively	390,922	566,451
Inventories	563,036	834,526
Prepaid expenses and other current assets	416,816	472,611
Total current assets	10,566,527	10,573,066
Fixed assets, net	229,313	293,897
Other long-term assets	923	10,484
Total assets	10,796,763	10,877,447
Current liabilities:	'	'
Accounts payable	322,896	257,361
Accrued compensation	386,004	647,288
Accrued expenses	870,196	948,843
Current portion of deferred revenue	68,812	134,185
Current portion of capital lease obligation	0	17,929
Total current liabilities	1,647,908	2,005,606
Deferred revenue, net of current portion	15,277	71,419
Common stock warrants	1,938,603	0
Total liabilities	3,601,788	2,077,025
Commitments and contingencies (Note 10)	'	'
Stockholders’ equity	'	'
Preferred stock, $0.001 par value, 5,000,000 shares authorized at December 31, 2013 and 2012; no shares issued and outstanding at December 31, 2013 and 2012	0	0
Common stock, $0.0001 par value; 50,000,000 authorized; 5,945,581 and 2,140,871 shares issued and outstanding at December 31, 2013 and 2012, respectively	595	214
Additional paid-in capital	153,806,460	147,393,151
Accumulated deficit	-146,612,080	-138,592,943
Total stockholders’ equity	7,194,975	8,800,422
Total liabilities and stockholders’ equity	$10,796,763	$10,877,447

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable, allowances	$35,895	$151,616
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,945,581	2,140,871
Common stock, shares outstanding	5,945,581	2,140,871

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	$5,278,806	$7,575,289	$10,396,775
Cost of revenues	2,194,259	3,588,806	4,722,069
Gross profit	3,084,547	3,986,483	5,674,706
Operating expenses:	'	'	'
Research and development	3,438,218	3,545,790	3,877,526
Sales and marketing	2,779,695	5,727,482	6,688,591
General and administrative	4,225,474	4,735,238	5,111,616
Total operating expenses	10,443,387	14,008,510	15,677,733
Loss from operations	-7,358,840	-10,022,027	-10,003,027
Interest income	5,666	14,474	21,922
Warrants offering costs	-376,306	0	0
Change in fair value of warrant liability	-289,657	0	0
Net loss	($8,019,137)	($10,007,553)	($9,981,105)
Net loss per common share applicable to common stockholders,basic and diluted (See Note 2, Summary of SignificantAccounting Policies)	($3.07)	($5.22)	($15.53)
Weighted average number of common shares outstanding, basic and diluted	2,862,094	1,918,723	642,513

Statements_of_Changes_in_Stock

Statements of Changes in Stockholders' Equity (USD $)	Total	Series A-1 Preferred Stock	Series A-2 Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2010	$20,198,972	$0	$0	$65	$138,803,192	($118,604,285)
Beginning Balance (in shares) at Dec. 31, 2010	'	0	0	644,376	'	'
Stock-based compensation expense	837,040	0	0	0	837,040	0
Issuance of common stock under employee stock purchase plan (in shares)	'	0	0	4,002	'	'
Issuance of common stock under employee stock purchase plan	33,614	0	0	0	33,614	0
Other issuances of stock from option plan (in shares)	'	0	0	2,342	'	'
Other issuances of stock from option plan	0	0	0	0	0	0
Net loss	-9,981,105	0	0	0	0	-9,981,105
Ending Balance at Dec. 31, 2011	11,088,521	0	0	65	139,673,846	-128,585,390
Ending Balance (in shares) at Dec. 31, 2011	'	0	0	650,720	'	'
Stock-based compensation expense	319,368	0	0	0	319,368	0
Issuance of common stock and warrants in public offering (In shares)	'	0	0	1,421,735	'	'
Issuance of common stock and warrants in public offering	7,377,048	0	0	142	7,376,906	0
Issuance of common stock on redemption of warrants (in shares)	'	0	0	23,127	'	'
Issuance of common stock on redemption of warrants	0	0	0	2	-2	0
Issuance of common stock under employee stock purchase plan (in shares)	'	0	0	8,895	'	'
Issuance of common stock under employee stock purchase plan	23,038	0	0	1	23,037	0
Other issuances of stock from option plan (in shares)	'	0	0	36,394	'	'
Other issuances of stock from option plan	0	0	0	4	-4	0
Net loss	-10,007,553	0	0	0	0	-10,007,553
Ending Balance at Dec. 31, 2012	8,800,422	0	0	214	147,393,151	-138,592,943
Ending Balance (in shares) at Dec. 31, 2012	'	0	0	2,140,871	'	'
Stock-based compensation expense	245,843	0	0	0	245,843	0
Issuance of common stock and preferred stock under Securities Purchase Agreement (in shares)	'	1,066.25	3,370.51	248,147	'	'
Issuance of common stock and preferred stock under Securities Purchase Agreement	876,786	1	3	25	876,757	0
Issuance of common stock upon conversion of preferred stock (in shares)	'	-1,066.25	-3,370.51	2,117,787	'	'
Issuance of common stock upon conversion of preferred stock	0	-1	-3	212	-208	0
Issuance of common stock upon exercise of warrants (in shares)	'	0	0	1,308,611	'	'
Issuance of common stock upon exercise of warrants	2,617,222	0	0	131	2,617,091	0
Reclassification of warrant liability to equity	2,362,259	0	0	0	2,362,259	0
Issuance of common stock under employee stock purchase plan (in shares)	'	0	0	16,094	'	'
Issuance of common stock under employee stock purchase plan	26,285	0	0	2	26,283	0
Common stock issued to settle incentive compensation obligations (in shares)	'	0	0	114,071	'	'
Common stock issued to settle incentive compensation obligations	285,295	0	0	11	285,284	0
Net loss	-8,019,137	0	0	0	0	-8,019,137
Ending Balance at Dec. 31, 2013	$7,194,975	$0	$0	$595	$153,806,460	($146,612,080)
Ending Balance (in shares) at Dec. 31, 2013	'	0	0	5,945,581	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows for operating activities:	'	'	'
Net loss	($8,019,137)	($10,007,553)	($9,981,105)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	150,663	297,097	376,932
Intangible asset impairment	0	0	192,500
Stock-based compensation	245,843	319,368	837,040
Inventory charges	151,558	234,848	98,556
Warrants offering costs	376,306	0	0
Change in fair value of warrant liability	289,657	0	0
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	175,529	343,267	682,846
Inventories	119,932	694,327	550,549
Prepaid expenses and other current assets	52,748	-76,880	110,400
Accounts payable	65,535	-371,854	370,060
Accrued expenses and compensation	-54,635	-530,141	240,433
Deferred revenue, deferred costs, and other	-108,907	-78,046	-256,609
Net cash used in operating activities	-6,554,908	-9,175,567	-6,778,398
Cash flows for investing activities:	'	'	'
Purchases of fixed assets	-86,079	-107,465	-110,987
Release of restricted cash	0	229,500	178,500
Net cash (used in) provided by investing activities	-86,079	122,035	67,513
Cash flows from financing activities:	'	'	'
Net proceeds from issuance of stock and warrants, including public offering and equity plans	7,155,191	7,482,884	33,614
Payments on capital lease	-17,929	-20,320	-19,092
Net cash provided by financing activities	7,137,262	7,462,564	14,522
Net increase (decrease) in cash and cash equivalents	496,275	-1,590,968	-6,696,363
Cash and cash equivalents, beginning of year	8,699,478	10,290,446	16,986,809
Cash and cash equivalents, end of year	9,195,753	8,699,478	10,290,446
Supplemental disclosure of cash flow information:	'	'	'
Common stock issued to settle incentive compensation obligation	285,295	0	0
Warrants issued under Securities Purchase Agreement initially recorded as a non-current liability	4,011,205	0	0
Common stock issued in exchange for warrants	0	127,885	0
Warrants issued in public offering	0	2,373,267	0
Warrants liability reclassified to additional paid-in capital upon exercise of warrants	$2,362,259	$0	$0

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation	'
	1. Description of Business and Basis of Presentation
	NeuroMetrix, Inc., or the Company, a Delaware corporation, was founded in June 1996. The Company is a medical device company focused on the neurological complications of diabetes. The Company believes that its substantial experience in developing medical devices to stimulate and measure peripheral nerve function uniquely position it to address unmet medical needs related to diabetic neuropathy. Neuropathy is a common and serious, often painful, complication of diabetes that may lead to foot ulcers and limb amputation. The Company has over a decade of experience in neuropathy detection, starting with approval in 1998 by the United States Food and Drug Administration, or FDA, of the NC-stat System, a point-of-care device for the performance of general purpose nerve conduction studies.
	In the first quarter of 2013, the Company completed product development and launched the SENSUSTM Pain Management System, or SENSUS, which is designed for relief of chronic, intractable pain. The Company believes this product will be attractive to pain medicine physicians, neurologists, endocrinologists, podiatrists, primary care physicians, and other physicians that are challenged with trying to manage pain in their patients with painful diabetic neuropathy, or PDN and other forms of neuropathic pain. The Company also markets the NC-stat® DPNCheck® device, which is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. NC-stat DPNCheck is designed to be used by endocrinologists, podiatrists, primary care physicians and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. Sales efforts for NC-stat DPNCheck are currently targeted at opportunities in the managed care market. The Company’s historical neurodiagnostic business is based on the ADVANCETM NCS/EMG System, or the ADVANCE System, which is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures and which is primarily used in physician offices and clinics. While the ADVANCE System contributes the majority of the Company’s revenues, the Company is not actively managing the ADVANCE business for growth.
	On June 4, 2013, the Company entered into a Securities Purchase Agreement, as amended (the “Purchase Agreement”), providing for the issuance of (i) 248,147 shares of common stock at a price of $2.095 per share, (ii)1,066.254 shares of Series A-1 convertible preferred stock (the “Series A-1 Preferred Stock”) at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 convertible preferred stock (the “Series A-2 Preferred Stock” and together with the Series A-1 Preferred Stock, the “Preferred Stock”) at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share (the “2013 Offering”). Each share of Preferred Stock was convertible into 477.327 shares of common stock, subject to adjustment, at any time at the option of the holder. The 2013 Offering resulted in approximately $5.0 million in gross proceeds, before deducting placement agent fees and other expenses. Net proceeds from the 2013 Offering were approximately $4.5 million. During the second half of 2013, all of the Series A-1 Preferred Stock and Series A-2 Preferred Stock was converted into a total of 2,117,787 shares of common stock. In addition, during the fourth quarter of 2013, warrants to purchase 1,308,611 shares of common stock were exercised and the same number of shares of common stock was issued. Proceeds from these exercises totaled $2.6 million. See Note 14, Stockholders’ Equity, for further details.
	The Company held cash and cash equivalents of $9.2 million as of December 31, 2013. The Company believes that these resources and the cash to be generated from expected product sales will be sufficient to meet its projected operating requirements through the first quarter of 2015. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products and the uncertainty of future revenues from new products; (b) changes the Company may make to the business that affect ongoing operating expenses; (c) changes the Company may make in its business strategy; (d) regulatory developments affecting the Company’s existing products and delays in the FDA approval process for products under development; (e) changes the Company may make in its research and development spending plans; and (f) other items affecting the Company’s forecasted level of expenditures and use of cash resources. Accordingly, the Company will need to raise additional funds to support its operating and capital needs in the second quarter of 2015 and beyond. The Company intends to obtain additional funding through public or private financing, collaborative arrangements with strategic partners, or through additional credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected.
	Certain prior period amounts have been adjusted to reflect the Company's 1-for-6 reverse stock split of its common stock completed on February 15, 2013 (see Note 15, Reverse Stock Splits, for further details).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
	The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of ninety days or less to be cash equivalents. Cash equivalents are recorded at cost which approximates fair value. The Company invests cash primarily in a money market account and other investments which management believes are subject to minimal credit and market risk.
	Concentrations of Credit Risk
	Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.
	At December 31, 2013, one customer accounted for 14% of accounts receivable and a second customer accounted for 12% of accounts receivable. For the years ended December 31, 2013, 2012, and 2011, no single customer accounted for more than 10% of revenue.
	The Company relies on in-house assembly and three third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company’s business, financial position, and results of operations.
	Inventories
	Inventories, consisting primarily of purchased components, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The Company writes down inventory to its net realizable value for excess or obsolete inventory.
	Fair Value
	The carrying amounts of the Company’s accounts receivable, accounts payable, and accrued expenses approximate their fair value at December 31, 2013 and 2012 due to the short-term nature of these assets and liabilities. The Company’s cash equivalents and its warrant liability are carried at fair value determined according to the fair value hierarchy described in Note  11.
	Revenue Recognition
	The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured.
	Revenues associated with the sale of the ADVANCE devices to customers and distributors are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. The revenues from the sale of an ADVANCE communication hub together with access to NeuroMetrix information systems are considered one unit of accounting and deferred and recognized on a straight-line basis over the estimated period of time that the Company provides the service associated with the information systems of three years. The resulting deferred revenue and deferred costs are presented as separate line items on the accompanying balance sheet. Revenues related to extended service agreements for the devices are recognized ratably over the term of the extended service agreement.
	Revenues associated with the sale of the SENSUS and NC-stat DPNCheck devices are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist.
	Revenues also include sales of consumables, including single use nerve specific electrodes and other accessories. These revenues are recognized upon shipment provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, and product returns are reasonably estimable.
	When multiple elements are contained in a single arrangement, the Company allocates revenue between the elements based on their relative selling prices. The Company determines selling price using vendor specific objective evidence, or VSOE, if it is available, third-party evidence, or TPE, if VSOE is not available, and best estimate of selling price, or BESP, if neither VSOE nor TPE are available. The Company generally expects that it will not be able to establish TPE due to the nature of the markets in which it competes, and, as such, it will typically determine selling price using VSOE or if not available, BESP. The objective of BESP is to determine the selling price of a deliverable on a standalone basis. The Company’s determination of BESP involves a weighting of several factors based on the specific facts and circumstances of an arrangement. Specifically, the Company considers the cost to produce the deliverable, the anticipated margin on that deliverable, the selling price and profit margin for similar parts, its ongoing pricing strategy, the value of any enhancements that have been built into the deliverable, and the characteristics of the varying markets in which the deliverable is sold.
	Revenue recognition involves judgments, including assessments of expected returns and expected customer relationship periods. The Company analyzes various factors, including a review of specific transactions, its historical returns, average customer relationship periods, customer usage, customer balances, and market and economic conditions. Changes in judgments or estimates on these factors could materially impact the timing and amount of revenues and costs recognized. Should market or economic conditions deteriorate, the Company’s actual return or bad debt experience could exceed its estimate.
	Certain product sales are made with a 30-day right of return. Since the Company can reasonably estimate future returns, it recognizes revenues associated with product sales that contain a right of return upon shipment and at the same time it records a sales return reserve, which reduces revenue and accounts receivable by the amount of estimated returns.
	Accounts Receivable
	Accounts receivable on the balance sheet are recorded net of the allowance for doubtful accounts receivable and the reserve for estimated returns. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company reviews its allowance for doubtful accounts and determines the allowance based on an analysis of customer past payment history, product usage activity, and recent communications between the Company and the customer. Past due balances are reviewed individually for collectibility. Account balances are written-off against the allowance when the Company feels it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers.
	Income Taxes
	The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company’s financial statements contain certain deferred tax assets, which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. In accordance with the provisions of the Income Taxes topic of the Codification, the Company is required to establish a valuation allowance if the likelihood of realization of the deferred tax assets is reduced based on an evaluation of objective verifiable evidence. Significant management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against those net deferred tax assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized.
	Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as well as similar state provisions. Ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
	If the Company has experienced a change of control, utilization of its NOL or tax credits carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Subsequent ownership changes could further impact the limitation in future years. Further, until a study is completed and any limitation known, no amounts are being presented as an uncertain tax position.
	A full valuation allowance has been provided against the Company’s NOL carryforwards and research and development credit carryforwards and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required.
	Management performed a two-step evaluation of all tax positions, ensuring that these tax return positions meet the “more likely than not” recognition threshold and can be measured with sufficient precision to determine the benefit recognized in the financial statements. These evaluations provide management with a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements certain tax positions that the Company has taken or expects to take on income tax returns.
	Research and Development
	Costs incurred in the research and development of the Company’s products are expensed as incurred. Included in research and development costs are wages, benefits, product design consulting, and other operating costs such as facilities, supplies, and overhead directly related to the Company’s research and development efforts.
	Product Warranty Costs
	The Company accrues estimated product warranty costs at the time of sale which are included in cost of sales in the statements of operations. The amount of the accrued warranty liability is based on historical information such as past experience, product failure rates, number of units repaired, and estimated cost of material and labor. The liabilities for product warranty costs of $4,719 and $18,629 at December 31, 2013 and 2012, respectively, are included in accrued expenses in the accompanying balance sheets.
	Fixed Assets and Long-Lived Assets
	Fixed assets are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Expenditures for repairs and maintenance are charged to expense as incurred. On disposal, the related assets and accumulated depreciation are eliminated from the accounts and any resulting gain or loss is included in the Company’s statement of operations. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvement or the remaining term of the lease.
	The Company periodically evaluates the recoverability of its fixed assets and other long-lived assets whenever events or changes in circumstances indicate that an event of impairment may have occurred. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to the assets operating performance and future undiscounted cash flows of the underlying assets. If the future undiscounted cash flows are less than their book value, an impairment may exist. The impairment is measured as the difference between the book value and the fair value of the underlying asset. Fair values are based on estimates of the market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is generally recognized ratably over the requisite service period. The Company uses the Black-Scholes option pricing model for determining the fair value of its stock options and amortizes its stock-based compensation expense using the straight-line method. The Black-Scholes model requires certain assumptions that involve judgment. Such assumptions are the expected share price volatility, expected life of options, expected annual dividend yield, and risk-free interest rate (See Note 3 — Stock-Based Compensation and Stockholders’ Equity).
	Net Loss per Common Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic net income per share. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period plus the dilutive effect of the weighted average number of outstanding instruments such as options, warrants, restricted stock, and preferred stock. Because the Company has reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:
		Years Ended December 31,
		2013		2012		2011
	Options		161,391		53,999		91,411
	Warrants		2,055,733		741,546		238,413
	Unvested restricted stock		22,387		31,699		4,725
	Total		2,239,511		827,244		334,549
	The Beneficial Conversion Feature, or BCF, recorded in the 2013 Offering has been recognized as a deemed dividend attributable to the Preferred Stock and is reflected as an adjustment in the calculation of earnings per share. See Note 14, Stockholders’ Equity, for further details.
	Net loss per common share applicable to common stockholders, basic and diluted was determined as follows:
		Years Ended December 31,
		2013		2012		2011
	Net loss	$	-8,019,137	$	-10,007,553	$	-9,981,105
	Deemed dividend attributable to preferred stockholders in		-766,872		—		—
	connection with beneficial conversion features
	Net loss applicable to common stockholders	$	-8,786,009	$	-10,007,553	$	-9,981,105
	Net loss per common share applicable to common	$	-3.07	$	-5.22	$	-15.53
	stockholders, basic and diluted
	Weighted average number of common shares outstanding,		2,862,094		1,918,723		642,513
	basic and diluted
	Advertising and Promotional Costs
	Advertising and promotional costs are expensed as incurred. Advertising and promotion expense was $151,000, $242,000, and $426,000 in the years ended December 31, 2013, 2012, and 2011, respectively.
	Accumulated Other Comprehensive Items
	For the years ended December 31, 2013, 2012, and 2011, the Company had no components of other comprehensive income or loss other than net loss.
Segments
The Company operates in one segment for the sale of medical equipment and consumables. Substantially all of the Company’s assets, revenues, and expenses for the years ended December 31, 2013, 2012, and 2011 were located at or derived from operations in the United States. Revenues from sales outside the United States accounted for approximately 16% of total revenues in 2013, 7% of total revenues in 2012, and 6% of total revenues in 2011.
Risks and Uncertainties
The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, customers’ reimbursement from third-party payers, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.
In late 2011, the Company launched NC-stat DPNCheck, which is a fast, accurate, and quantitative nerve conduction test for the assessment of systemic neuropathies such as DPN. In early 2013 the Company launched SENSUS for the treatment intractable pain, including pain associated with diabetic neuropathy. The future prospects of the Company are closely tied to its success with NC-stat DPNCheck and SENSUS in market acceptance and growth in future revenues.
Recently Issued or Adopted Accounting Pronouncements
There have been no recent accounting pronouncements or changes in accounting pronouncements since the recent accounting pronouncements described in the Company's 2012 Form 10-K that are of significance to the Company.

StockBased_Compensation_and_St

Stock-Based Compensation and Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Share-based Compensation [Abstract]

'

Stock-Based Compensation and Stockholdersb Equity

'

3. Stock-Based Compensation and Stockholders’ Equity

Stock-Based Compensation

During 2004, the Company adopted the 2004 Stock Option and Incentive Plan, as amended and restated in 2006, 2008, 2009, and 2012. At the Annual Meeting of Stockholders held on May 6, 2013, the stockholders of the Company approved the Company’s Fifth Amended and Restated 2004 Stock Option and Incentive Plan (the “2004 Stock Plan”), which, among other things, increased the number of shares of the Company’s common stock authorized for issuance thereunder by 300,000 shares. The 2004 Stock Plan, among other things, provides for granting of incentive and nonqualified stock option and stock bonus awards to officers, employees and outside consultants. Outstanding options under the 2004 Stock Plan generally vest over three or four years and terminate 10 years after the grant date, or earlier if the option holder is no longer an executive officer, employee, consultant, advisor or director, as applicable, of the Company. As of December 31, 2013, 576,279 shares of common stock were authorized for issuance under the 2004 Stock Plan, of which 128,644 shares had been issued, 309,046 shares were subject to outstanding options at a weighted average exercise price of $12.37 per share and 97,440 shares were available for future grant.

During May 2009, the Company adopted the 2009 Non-Qualified Inducement Stock Plan (the “2009 Inducement Plan”). The 2009 Inducement Plan is intended to encourage and enable employees, including prospective employees, of the Company upon whose judgment, initiative, and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. The 2009 Inducement Plan, among other things, provides for the granting of awards, including non-qualified stock options, restricted stock, and unrestricted stock. As of December 31, 2013, 400,000 shares of common stock were authorized for issuance under the 2009 Inducement Plan, of which no shares had been issued and no shares were outstanding.

The exercise price of each stock option issued under the 1996 and 1998 Stock Plans was specified by the Board of Directors at the time of grant. The exercise price of stock options awarded under the 2004 Stock Plan and the 2009 Inducement Plan may not be less than the fair market value of the common stock on the date of the option grant. For holders of more than 10% of the Company’s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company’s common stock at the date of grant and for a term not to exceed five years.

In June 2004, the Company adopted the 2004 Employee Stock Purchase Plan (the “2004 ESPP”). All of the Company’s employees who had been employed by the Company for at least 60 days and whose customary employment is for more than 20 hours per week and for more than five months in any calendar year were eligible to participate and any employee who owned 5% or more of the voting power or value of the Company’s stock was not eligible to participate. The 2004 ESPP authorized the issuance of up to a total of 10,417 shares of the Company’s common stock to participating employees.

In May 2010, the Company adopted the 2010 Employee Stock Purchase Plan (the “2010 ESPP”). The 2010 ESPP initially authorized the issuance of up to a total of 6,945 shares, of the Company’s common stock to participating employees plus an annual increase on the first day of each of the Company's fiscal years beginning in 2011, equal to the lesser of (i) 6,945 shares, (ii) 1 percent of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the Board. At the Company’s Annual Meeting of Stockholders held on May 14, 2012, the stockholders of the Company approved the Company’s Amended and Restated 2010 Employee Stock Purchase Plan (the “Amended and Restated 2010 ESPP”), which, among other things, increased the number of shares of the Company’s common stock authorized for issuance thereunder by 16,667 shares. All of the Company’s full-time employees and certain part-time employees are eligible to participate in the Amended and Restated 2010 ESPP. For part-time employees to be eligible, they must have customary employment of more than five months in any calendar year and more than 20 hours per week. Employees who, after exercising their rights to purchase shares under the Amended and Restated 2010 ESPP, would own shares representing 5% or more of the voting power of the Company’s common stock, are ineligible to participate.

Under the Amended and Restated 2010 ESPP, participating employees can authorize the Company to withhold up to 10% of their earnings during consecutive six-month payment periods for the purchase of the shares. At the conclusion of each period, participating employees can purchase shares at 85% of the lower of their fair market value at the beginning or end of the period. The Amended and Restated 2010 ESPP is regarded as a compensatory plan. For the years ended December 31, 2013 and 2012 the Company issued 16,094 and 8,895 shares of its common stock, respectively, under the Amended and Restated 2010 ESPP and the 2010 ESPP, respectively. As of December 31, 2013, there were 22,338 remaining shares to be issued under the Amended and Restated 2010 ESPP.

The Company uses the Black-Scholes option pricing model for determining the fair value of shares of common stock issued or to be issued under the 2010 ESPP and the Amended and Restated 2010 ESPP. The following assumptions are used in determining fair value: The risk-free interest rate assumption is based on the United States Treasury’s constant maturity rate for a six month term (corresponding to the expected option term) on the date the option was granted. The expected dividend yield is zero because the Company does not currently pay dividends nor expects to do so during the expected option term. An expected term of six months is used based on the duration of each plan offering period. The volatility assumption is based on a consideration of stock price volatility over the most recent period of time corresponding to the expected term and is also based on expected future stock price volatility.

The weighted average grant-date fair value of stock options used in the calculation of stock-based compensation expense in the accompanying statement of operations for the years ended December 31, 2013, 2012, and 2011 is calculated using the following assumptions:

Years Ended December 31,

2013

2012

2011

Risk-free interest rate

1.4 – 1.7%

0.6% – 0.9%

0.9% – 2.3%

Expected dividend yield

—

—

—

Expected option term

5 years

5 years

5 – 6 years

Volatility

70.00%

70.00%

70.00%

The risk-free interest rate assumption is based on the United States Treasury’s constant maturity rate for a five year term (corresponding to the expected option term) on the date the option was granted. The expected dividend yield is zero as the Company does not currently pay dividends nor expects to do so during the expected option term. The expected option term of five years is estimated based on an analysis of actual option exercises and a review of comparable medical device companies. The volatility assumption is based on weekly historical volatility during the time period that corresponds to the expected option term, a review of comparable medical device companies and expected future stock price volatility. The pre-vesting forfeiture rate is based on the historical and projected average turnover rate of employees.

A summary of option activity for the year ended December 31, 2013 is presented below:

Number of

Weighted Average

Weighted Average Remaining

Aggregate

Options

Exercise Price

Contractual Life (in years)

Intrinsic

Value

Outstanding at December 31, 2012

51,550

$

73.38

Granted

265,000

1.76

Exercised

—

—

Forfeited

-5,945

19.89

Expired

-459

81

Outstanding at December 31, 2013

310,146

13.2

9.02

$

306,925

Vested or expected to vest at

285,291

14.2

8.96

278,018

December 31, 2013

Exercisable at December 31, 2013

41,620

85.01

5.59

—

Expected to vest options are determined by applying the pre-vesting forfeiture rate to the total outstanding options. Aggregate intrinsic value represents the total pre-tax intrinsic value (the aggregate difference between the closing stock price of the Company’s common stock as of December 31, 2013, as applicable, and the exercise price for the in-the-money options) that would have been received by the option holders if all the in-the-money options had been exercised on December 31, 2013.

The weighted average per share grant-date fair values of options granted during the years ended December 31, 2013, 2012, and 2011 was $1.02, $2.67, and $11.34, respectively.

The aggregate intrinsic value of options issued or exercised during each of the years ended December 31, 2013, 2012, and 2011 was $0.

Total unrecognized stock-based compensation costs related to non-vested stock options was $247,468, which related to 286,022 shares with a per share weighted fair value of $0.87 as of December 31, 2013. This unrecognized cost is expected to be recognized over a weighted average period of approximately 0.4 years.

Stock options granted to non-employees are recorded at fair value and adjusted to market over the vesting period. The Company determines fair value using the Black-Scholes option pricing model, an expected term equal to the option term, a risk-free interest rate corresponding to the expected term, a stock price volatility over the most recent period of time corresponding to the expected term and also based on expected future stock price volatility, and a dividend yield of zero. There were no options granted to non-employees during the years ended December 31, 2013, 2012 or 2011.

Beginning in 2010, certain employees have been granted restricted stock. During 2013, 2012, and 2011, the Company granted 2,000, 37,167, and 3,630 shares of restricted stock, respectively. The restricted stock vests based on continuing employment. The fair value of restricted stock is calculated based on the closing sale price of the Company’s common stock on the date of issuance.

A summary of restricted stock activity for the year ended December 31, 2013 is presented below:

Restricted Shares

Weighted

Average

Grant Date

Fair Value

Restricted shares at December 31, 2012

38,272

$

5.25

Granted

2,000

1.9

Vested

-19,421

-5.66

Canceled

-3,375

-4.2

Restricted shares at December 31, 2013

17,476

$

4.62

During the years ended December 31, 2013 and 2012, certain employees, in lieu of paying withholding taxes on the vesting of restricted stock, authorized the withholding of an aggregate of 4,214 and 721 shares, respectively, of common stock to satisfy the minimum tax withholding requirements related to such vesting. Shares withheld were calculated using the market price of the common stock.

Cash received from option exercises and purchases under the 2004 ESPP and the 2010 ESPP for the years ended December 31, 2013, 2012, and 2011 was $26,000, $23,000, and $34,000, respectively. The Company issues new shares upon option exercises, purchases under the Company’s ESPPs, and vesting of restricted stock.

The Company recorded stock-based compensation expense of $246,000, $319,000, and $837,000 for the years ended December 31, 2013, 2012, and 2011, respectively.

Stockholders’ Equity

On June 4, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which it issued (i) 248,147 shares of common stock at a price of $2.095 per share, (ii) 1,066.254 shares of Series A-1 Preferred Stock at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 Preferred Stock at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share. During the second half of 2013, all of the Series A-1 Preferred Stock and Series A-2 Preferred Stock was converted into a total of 2,117,787 shares of common stock. In addition, during the fourth quarter of 2013, warrants to purchase 1,308,611 shares of common stock were exercised and the same number of shares of common stock was issued. Proceeds from these exercises totaled $2.6 million. See Note 14, Stockholders’ Equity, for further details.

In March 2013, the Company awarded certain executives an aggregate of 119,370 shares of fully vested common stock with a value of $285,300 in settlement of 2012 incentive compensation obligations. The value of the shares issued reflected the $2.39 closing price of the Company’s common stock as reported on the NASDAQ Capital Market on March 4, 2013.

In March 2012, the Company issued 23,127 shares of its common stock in satisfaction of the Company’s obligation to redeem certain warrants issued by the Company pursuant to Securities Purchase Agreements dated as of September 8, 2009. No cash was paid to redeem the warrants.

On February 13, 2012, the Company completed a public offering of 1,421,735 Units at a price of $6.00 per Unit (the “2012 Offering”). Each Unit consisted of one share of the Company’s common stock and one warrant to purchase one half of a share of the Company’s common stock at an exercise price of $6.90 per share. The Company issued 1,421,735 shares of common stock and warrants to purchase 781,955 shares of common stock and received proceeds, net of discounts, commissions and expenses, of approximately $7.4 million. See Note 14, Stockholders’ Equity, for further details.

As of December 31, 2013, the Company had 50,000,000 shares of common stock authorized and 5,945,581 shares issued and outstanding. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are not entitled to receive dividends unless declared by the Board of Directors.

At December 31, 2013, the Company has reserved authorized shares of common stock for future issuance as follows:

Warrants

1,839,278

Outstanding stock options

310,146

Possible future issuance under inducement plan

400,000

Possible future issuance under stock option plans

97,440

Possible future issuance under employee stock purchase plan

22,338

Total

2,669,202

On March 7, 2007, the Company’s Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company’s common stock to shareholders of record as of the close of business on March 8, 2007. As of December 31, 2013 and 2012, there was no preferred stock outstanding.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	4. Intangible Assets
	In January 2009, the Company acquired certain technological and intellectual property assets from Cyberkinetics Neurotechnology Systems, Inc., or Cyberkinetics, and Andara Life Science, Inc., a wholly-owned subsidiary of Cyberkinetics, for $350,000 in cash. The Company had been amortizing these intangible assets using the straight-line method over their economic lives, which was estimated to be five years. Research and development expenses included amortization of this technological and intellectual property of $17,500 for the quarter March 31, 2011. Following its decision to terminate development work related to this technology, the Company recorded within research and development expense in the second quarter of 2011 an impairment charge of $192,500 for the remaining unamortized balance of these assets. There was no amortization expense in the years ended December 31, 2013 and 2012.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	5. Inventories
	Inventories consist of the following:
		December 31,
		2013		2012
	Purchased components	$	205,320	$	187,567
	Finished goods		357,716		646,959
		$	563,036	$	834,526

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Fixed Assets	'
	6. Fixed Assets
	Fixed assets consist of the following:
				December 31,
			Estimated Useful Life (Years)	2013		2012
	Computer and laboratory equipment		3	$	1,748,566	$	2,689,519
	Furniture and equipment		3		249,377		644,034
	Production equipment		7		997,297		997,297
	Leasehold improvements		*		185,255		179,997
					3,180,495		4,510,847
	Less – accumulated depreciation				-2,951,182		-4,216,950
				$	229,313	$	293,897
		*	Lesser of life of lease or estimated useful life.
	Depreciation expense was $150,663, $239,168, and $359,432 for the years ended December 31, 2013, 2012, and 2011, respectively.
	A capital lease was included as a component of furniture and equipment at December 31, 2012. Amortization of assets under this capital lease is included in depreciation expense. See Note 10 —  Commitments and Contingencies for more information regarding this capital lease.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	7. Accrued Expenses
	Accrued expenses consist of the following for the years ended December 31, 2013 and 2012:
		December 31,
		2013		2012
	Technology fees	$	450,000	$	450,000
	Professional services		263,642		248,759
	Clinical study obligations		51,424		24,490
	Sales taxes		32,688		62,385
	Supplier obligations		—		105,132
	Other		72,442		58,077
		$	870,196	$	948,843

Restructuring_Related_Activity

Restructuring Related Activity	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Related Activity	'
	8. Restructuring Related Activity
	In January 2011, the Company announced it had restructured its neurodiagnostic activities to more efficiently focus its efforts on its installed base of active accounts, to shift distribution to independent sales representatives, and to reduce cash consumption. Twenty-five positions were eliminated, primarily in sales. Charges totaled $2.2 million related to severance costs and inventory. Approximately $2.0 million, consisting of $0.2 million in severance and $1.8 million in inventory charges, was recorded as of December 31, 2010 and the balance of approximately $0.2 million in severance was recorded in 2011. The full amount of the charge was paid as of December 31, 2011.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9. Income Taxes
	Current income tax expense (benefit) attributable to continuing operations consists of the following for the years ended December 31, 2013, 2012, and 2011.
		Years Ended December 31,
		2013		2012		2011
	Federal		—		—		—
	State		—		—		—
	Total		—		—		—
	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2013, 2012, and 2011.
		Years Ended December 31,
		2013		2012		2011
	Federal tax provision (benefit) rate	-34	%	-34	%	-34	%
	State tax provision, net of federal provision	-4.8		-3.5		-3.4
	Permanent items	3.4		0.8		1.9
	Federal research and development credits	-1.7		—		-0.5
	Valuation allowance	37.1		36.7		36
	Effective income tax rate	—	%	—	%	—	%
	The Company’s deferred tax assets consist of the following:
		December 31,
		2013		2012
	Deferred tax assets:
	Net operating loss carryforwards	$	32,253,602	$	30,514,469
	Research and development credit carryforwards		1,735,265		1,547,374
	Accrued expenses		493,075		643,952
	Stock-based compensation		565,077		593,131
	Other		1,061,212		1,048,541
	Total gross deferred tax assets		36,108,231		34,347,467
	Valuation allowance		-36,108,231		-34,347,467
	Net deferred tax assets	$	—	$	—
	At December 31, 2013, the Company has federal and state net operating loss carryforwards (“NOL”) of $97.1 million and $18.6 million, respectively, as well as federal and state tax credits of $1.1 million and $977,000, respectively, which may be available to reduce future taxable income and the related taxes thereon. This amount includes tax benefits of $3.9 million and $71,000 attributable to NOL and tax credit carryforwards, respectively, that result from the exercise of employee stock options. The tax benefit of these items will be recorded as a credit to additional paid-in capital upon realization of the deferred tax asset or reduction in income taxes payable. The federal NOL’s begin to expire in 2019 and the state NOL’s begin to expire in 2014. The federal and state research and development credits both begin to expire in 2018.
	In accordance with the provisions of the Income Taxes topic of the Codification, the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating losses. Management has determined that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets and, as a result, a valuation allowance of approximately and $36.1 million and $34.3 million has been established at December 31, 2013 and 2012, respectively.
	Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as well as similar state provisions. Ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
	If the Company has experienced a change of control, utilization of its NOL or tax credits carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Subsequent ownership changes could further impact the limitation in future years. Further, until a study is completed and any limitation known, no amounts are being presented as an uncertain tax position.
	A full valuation allowance has been provided against the Company’s NOL carryforwards and research and development credit carryforwards and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Operating Leases
	Lease Agreement with Fourth Avenue LLC
	In June 2013, the Company amended the Lease Agreement dated October 18, 2000 between Fourth Avenue LLC and the Company for office and engineering laboratory space to extend the term of the lease through March 31, 2015. Base rent for the period January 2014 through March 2015 is $52,917 per month.
	Future minimum lease payments under noncancelable operating leases as of December 31, 2013 are as follows:
	2014	$	635,004
	2015		158,751
	Total minimum lease payments	$	793,755
	Total recorded rent expense was $635,004, $709,164, and $764,754 for the years ended December 31, 2013, 2012, and 2011, respectively. The Company records rent expense on its facility lease on a straight-line basis over the lease term.
	Capital Lease
	In October 2010, the Company entered into a non-cancelable capital lease for copiers located at its corporate headquarters valued at $60,410, which expired in September 2013.
	Future minimum lease payments under the capital lease as of December 31, 2012 were as follows:
	2013	$	18,446
	Total minimum lease payments		18,446
	Less: Amount representing imputed interest		517
	Present value of future minimum lease payments	$	17,929
	Other Commitments
	At December 31, 2013, other commitments, comprised of purchase orders, totaled approximately $147,806.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	11. Fair Value Measurements
	The Fair Value Measurements and Disclosures Topic of the Codification defines fair value, establishes a framework for measuring fair value in applying generally accepted accounting principles, and expands disclosures about fair value measurements. This Codification topic identifies two kinds of inputs that are used to determine the fair value of assets and liabilities: observable and unobservable. Observable inputs are based on market data or independent sources while unobservable inputs are based on the Company’s own market assumptions. Once inputs have been characterized, this Codification topic requires companies to prioritize the inputs used to measure fair value into one of three broad levels. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values identified by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values identified by Level 3 inputs are unobservable data points and are used to measure fair value to the extent that observable inputs are not available. Unobservable inputs reflect the Company’s own assumptions about the assumptions that market participants would use at pricing the asset or liability.
	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
					Fair Value Measurements at December 31, 2013 Using
		December 31,			Quoted Prices in Active Markets		Significant		Significant Unobservable
		2013			for Identical Assets		Other Observable		Inputs (Level 3)
					(Level 1)		Inputs
							(Level 2)
	Assets:
	Cash equivalents	$	3,926,600		$	3,926,600	$	—	$	—
	Total	$	3,926,600		$	3,926,600	$	—	$	—
	Liabilities:
	Common stock warrants	$	1,938,603		$	—	$	—		1,938,603
	Total	$	1,938,603		$	—	$	—	$	1,938,603
				Fair Value Measurements at December 31, 2012 Using
		December 31,			Quoted Prices in Active Markets		Significant		Significant Unobservable
		2012			for Identical Assets		Other Observable		Inputs (Level 3)
					(Level 1)		Inputs
							(Level 2)
	Assets:
	Cash equivalents	$	519,242		$	519,242	$	—	$	—
	Total	$	519,242		$	519,242	$	—	$	—
	Due to the lack of market quotes relating to our common stock warrants, the fair value of the common stock warrants was determined at December 31, 2013 using the Black-Scholes model, which is based on Level 3 inputs. As of December 31, 2013, inputs used in the Black-Scholes model include our stock price as of that date of $2.92, exercise price of $2.00, expected volatility of 67.60%, risk free interest rate of 1.71%, expected term of approximately four years and 5 months, and no dividends. The assumptions used may change as the underlying sources of these assumptions and market conditions change. Based on this calculation, the Company recorded a common stock warrants liability of $1.9 million at December 31, 2013. In addition, 1.3 million warrants were exercised during the fourth quarter of 2013 and these warrants were adjusted to their fair value at the dates of exercise. The total liability for the exercised warrants of $2.4 million was then reclassified to additional paid-in capital. The Company did not have any financial liabilities carried at fair value as of December 31, 2012.
	The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the year ended December 31, 2013:
	Balance at December 31, 2012	$	—
	Initial fair value of warrants at issuance in June 2013		4,011,205
	Change in fair value of warrant liability		289,657
	Reclassification of liability to additional paid-in capital upon exercise of warrants		-2,362,259
	Balance at December 31, 2013	$	1,938,603

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Retirement Plan	'
	12. Retirement Plan
	The Company established a 401(k) defined contribution savings plan for its employees who meet certain service period and age requirements. Contributions are permitted up to the maximum allowed under the Internal Revenue Code of each covered employee’s salary. The savings plan permits the Company to contribute at its discretion. For the years ended December 31, 2013, 2012, and 2011 the Company made no contributions to the plan.

Credit_Facility

Credit Facility	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Credit Facility	'
	13. Credit Facility
	The Company is party to a Loan and Security Agreement, or the Credit Facility, with a bank. As of December 31, 2013 the Credit Facility permitted the Company to borrow up to $2.5 million on a revolving basis. The Credit Facility was subsequently amended and extended until January 15, 2015. Under terms of the amended and extended Agreement the amount of the Credit Facility will remain at $2.5 million until December 31, 2014. Thereafter, until its expiry on January 15, 2015, the Credit Facility will be reduced to $750,000 if the Company has not yet completed an equity offering as defined in the Agreement. Amounts borrowed under the Credit Facility will bear interest equal to the prime rate plus 0.5%. Any borrowings under the Credit Facility will be collateralized by the Company’s cash, accounts receivable, inventory, and equipment. The Credit Facility includes traditional lending and reporting covenants. These include certain financial covenants applicable to liquidity that are to be maintained by the Company. As of December 31, 2013, the Company was in compliance with these covenants and had not borrowed any funds under the Credit Facility. The amount of $225,000 of the Credit Facility limit is restricted to support a letter of credit issued in favor of the Company’s landlord in the lease of its facilities in Waltham, Massachusetts. Consequently, the amount available for borrowing under the Credit Facility as of December 31, 2013 was $2,275,000.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholdersb Equity	'
	14. Stockholders’ Equity
	On June 4, 2013, the Company entered into a Purchase Agreement providing for the issuance of (i) 248,147 shares of common stock at a price of $2.095 per share, (ii) 1,066.254 shares of Series A-1 Preferred Stock at a price of $1,000 per share, (iii) 3,370.510 shares of Series A-2 Preferred Stock at a price of $1,000 per share, and (iv) five year warrants to purchase up to 2,365,934 shares of common stock with an exercise price of $2.00 per share. The 2013 Offering resulted in approximately $5.0 million in gross proceeds, before deducting placement agent fees and other expenses. Net proceeds from the 2013 Offering were approximately $4.5 million.
	Each share of Preferred Stock had a stated value of $1,000 and was convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value by the initial conversion price of $2.095, which was subject to adjustment as provided in each Certificate of Designation for the Preferred Stock. The Preferred Stock had no dividend rights, liquidation preference or other preferences over common stock and had no voting rights except as provided in each Certificate of Designation for the Preferred Stock and as required by law. During the second half of 2013, all of the Series A-1 Preferred Stock and Series A-2 Preferred Stock was converted into a total of 2,117,787 shares of common stock. The warrants to purchase 2,365,934 shares of common stock were exercisable immediately, have a five-year term, and a per share exercise price of $2.00. During the fourth quarter of 2013, warrants to purchase 1,308,611 shares of common stock were exercised and the same number of shares of common stock was issued. Proceeds from these exercises totaled $2.6 million.
	The terms and conditions of the Preferred Stock were evaluated based on the guidance of the Derivatives and Hedging topic of the Codification to determine if the conversion feature was an embedded derivative requiring bifurcation. It was concluded that bifurcation was not required because the conversion feature was clearly and closely related to the Preferred Stock. The conversion price at which shares of Preferred Stock were convertible into shares of common stock was determined to be lower than the fair value of common stock at the date of the Purchase Agreement. This “in-the-money” beneficial conversion feature, or BCF, required separate recognition and measurement of its intrinsic value (i.e., the amount of the increase in value that holders of Preferred Stock would realize upon conversion based on the value of the conversion shares on the date of the Purchase Agreement). The BCF measurement totaled $766,900, an amount limited by the transaction proceeds which had been allocated to the Preferred Stock. Because there was not a stated redemption date for the shares of Preferred Stock, the BCF was recognized as a deemed dividend attributable to the Preferred Stock and is reflected as an adjustment in the calculation of earnings per share.
	The warrants issued in connection with the 2013 Offering are within the scope of the Derivatives and Hedging topic of the Codification. This Codification topic requires issuers to classify as liabilities (or assets under certain circumstances) financial instruments which require an issuer to settle in registered shares. As the warrants are required to be settled in registered shares when exercised, the Company has reflected the warrants as a liability in the balance sheet. The fair value of the warrants at the date of the 2013 Offering was estimated at $4.0 million using a Black-Scholes model with the following assumptions: stock price of $2.60, exercise price of $2.00, expected volatility of 73.6%, risk free interest rate of 1.05%, expected term of five years, and no dividends. The warrants were revalued at June 30, 2013, September 30, 2013, and December 31, 2013 using the same Black-Scholes model. The liability for the remaining warrants was reflected in the balance sheet at December 31, 2013 in the amount of $1.9 million and non-operating expense of $290,000 has been recorded through December 31, 2013. The Company will continue to revalue unexercised warrants at each reporting period over the life of the warrants using the Black-Scholes model and the changes in the fair value of the warrants will be recognized in the Company's statement of operations.
	On July 26, 2013, the Company filed a Registration Statement on Form S-8 to register 386,111 additional shares of the Company’s common stock for issuance under the Company’s 2009 Non-Qualified Inducement Stock Plan (the “2009 Stock Plan”). An aggregate of 13,889 shares of common stock to be issued under the 2009 Stock Plan were previously registered on June 3, 2009. The amount previously registered reflects two 1-for-6 reverse splits of the Company’s common stock completed on September 1, 2011 and February 15, 2013.
	On February 13, 2012, the Company completed a public offering of 1,421,735 Units at a price of $6.00 per Unit (the “Offering”). Each Unit consists of one share of the Company’s common stock and one warrant to purchase one half of a share of the Company’s common stock. The Company issued 1,421,735 shares of common stock and warrants to purchase 710,868 shares of common stock and received offering proceeds, net of discounts, commissions and expenses, of approximately $7.4 million. Each warrant entitles the holder to purchase at any time during the period commencing 180 days after the date of the Offering until the date five years following the closing date of the Offering, one half of a share of the Company’s common stock. Two warrants would need to be exercised to acquire one share of the Company’s common stock at an exercise price of $6.90 (115% of the aggregate offering price for a unit). In addition, the placement agent for the Offering was issued warrants to purchase 71,087 shares of common stock (equal to 5.0% of the number of shares of common stock included in the Units sold in the Offering) at an exercise price of $7.50 per share (125% of the aggregate offering price for a Unit). The placement agent’s warrants will be exercisable at any time beginning one year after the date of issuance and will expire on the fifth anniversary of the effectiveness of the registration statement related to the Offering.
	The fair value of the warrants was estimated at $2.4 million using a Black-Scholes model with the following assumptions: expected volatility of 73.5%, risk free interest rate of 0.85%, expected life of five years, and no dividends. The volatility assumption is based on weekly historical volatility during the time period that corresponds to the expected option term, a review of comparable medical device companies, and expected future stock price volatility. The relative fair value of the warrants was recorded as equity.

Reverse_Stock_Splits

Reverse Stock Splits	12 Months Ended
	Dec. 31, 2013
Reverse Stock Split Disclosure [Abstract]	'
Reverse Stock Splits	'
	15. Reverse Stock Splits
	On September 1, 2011, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, to effect a 1-for-6 reverse stock split of its common stock, or the Reverse Stock Split. This action had previously been approved by the Company’s stockholders at the Company’s annual meeting held on May 16, 2011. As a result of the Reverse Stock Split, every six shares of the Company’s pre-reverse split common stock were combined and reclassified into one share of its common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive a fractional share in connection with the Reverse Stock Split received a cash payment in lieu thereof. The par value and other terms of the common stock were not affected by the Reverse Stock Split.
	The Company’s shares outstanding immediately prior to the Reverse Stock Split totaled 23,331,646, which were adjusted to 3,888,607 shares outstanding as a result of the Reverse Stock Split. On February 15, 2013, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, to effect a second 1-for-6 reverse stock split of its common stock, or the Second Reverse Stock Split. This action had previously been approved by the Company’s stockholders at a special meeting of stockholders held on December 7, 2012. As a result of the Second Reverse Stock Split, every six shares of the Company’s pre-reverse split common stock were combined and reclassified into one share of its common stock. No fractional shares were issued in connection with the Second Reverse Stock Split. Stockholders who otherwise would have been entitled to receive a fractional share in connection with the Second Reverse Stock Split received a cash payment in lieu thereof. The par value and other terms of the common stock were not affected by the Second Reverse Stock Split.
	The Company’s shares outstanding immediately prior to the Second Reverse Stock Split totaled 12,845,228. These were adjusted to 2,140,871 shares outstanding as a result of the Reverse Stock Split.

Management_Retention_and_Incen

Management Retention and Incentive Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Management Retention and Incentive Plan	'
	16. Management Retention and Incentive Plan
	On August 2, 2012, the Company adopted the Management Retention and Incentive Plan (the “Plan”), under which a portion of the consideration payable upon a change of control transaction, as defined in the Plan, would be paid in cash to certain executive officers and key employees and recorded as compensation expense within the Statement of Operations during the period in which the change of control transaction occurs. The Plan is structured to work in conjunction with, and not replace, the Company’s other incentive programs and is designed to provide market-based incentives which will be reduced over time by any future equity grants to participants.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule II-Valuation and Qualifying Accounts	'
	Schedule II — Valuation and Qualifying Accounts
	Description		Balance at		Charged to		Charged to		Recoveries/			Balance at
			Beginning of Period		costs and		other		(Deductions)			End of
					expenses		accounts					Period
	31-Dec-13
	Allowance for Doubtful		$	130,000	$	111,296		—	$	-206,296			35,000
	Accounts
	Sales Returns Reserve			21,616		—		38,278		-58,999			895
	Deferred Tax Asset			34,347,467		2,976,809		—		-1,216,045	-2		36,108,231
	Valuation Allowance
	31-Dec-12
	Allowance for Doubtful		$	286,612	$	-12,999	$	—	$	-143,613	-1	$	130,000
	Accounts
	Sales Returns Reserve			13,302		—		180,066		-171,752	-1		21,616
	Deferred Tax Asset			30,487,085		3,900,388		—		-40,006	-2		34,347,467
	Valuation Allowance
	31-Dec-11
	Allowance for Doubtful		$	379,100	$	30,825	$	—	$	-123,313	-1	$	286,612
	Accounts
	Sales Returns Reserve			26,865		—		272,607		-286,170	-1		13,302
	Deferred Tax Asset			28,670,035		3,803,223		—		-1,986,173	-2		30,487,085
	Valuation Allowance
		-1	Net write-offs.
		-2	Expiration of Federal and State Net Operating Loss Carryforwards and other reductions.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates and Assumptions	'
	Use of Estimates and Assumptions
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
	The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of ninety days or less to be cash equivalents. Cash equivalents are recorded at cost which approximates fair value. The Company invests cash primarily in a money market account and other investments which management believes are subject to minimal credit and market risk.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.
	At December 31, 2013, one customer accounted for 14% of accounts receivable and a second customer accounted for 12% of accounts receivable. For the years ended December 31, 2013, 2012, and 2011, no single customer accounted for more than 10% of revenue.
	The Company relies on in-house assembly and three third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company’s business, financial position, and results of operations.
Inventories	'
	Inventories
	Inventories, consisting primarily of purchased components, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The Company writes down inventory to its net realizable value for excess or obsolete inventory.
Fair Value	'
	Fair Value
	The carrying amounts of the Company’s accounts receivable, accounts payable, and accrued expenses approximate their fair value at December 31, 2013 and 2012 due to the short-term nature of these assets and liabilities. The Company’s cash equivalents and its warrant liability are carried at fair value determined according to the fair value hierarchy described in Note  11.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement exists, delivery has occurred and risk of loss has passed, the seller’s price to the buyer is fixed or determinable, and collection is reasonably assured.
	Revenues associated with the sale of the ADVANCE devices to customers and distributors are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist. The revenues from the sale of an ADVANCE communication hub together with access to NeuroMetrix information systems are considered one unit of accounting and deferred and recognized on a straight-line basis over the estimated period of time that the Company provides the service associated with the information systems of three years. The resulting deferred revenue and deferred costs are presented as separate line items on the accompanying balance sheet. Revenues related to extended service agreements for the devices are recognized ratably over the term of the extended service agreement.
	Revenues associated with the sale of the SENSUS and NC-stat DPNCheck devices are recognized upon shipment, provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, product returns are reasonably estimable, and no continuing obligations exist.
	Revenues also include sales of consumables, including single use nerve specific electrodes and other accessories. These revenues are recognized upon shipment provided that the selling price is fixed or determinable, persuasive evidence of an arrangement exists, collection of receivables is reasonably assured, and product returns are reasonably estimable.
	When multiple elements are contained in a single arrangement, the Company allocates revenue between the elements based on their relative selling prices. The Company determines selling price using vendor specific objective evidence, or VSOE, if it is available, third-party evidence, or TPE, if VSOE is not available, and best estimate of selling price, or BESP, if neither VSOE nor TPE are available. The Company generally expects that it will not be able to establish TPE due to the nature of the markets in which it competes, and, as such, it will typically determine selling price using VSOE or if not available, BESP. The objective of BESP is to determine the selling price of a deliverable on a standalone basis. The Company’s determination of BESP involves a weighting of several factors based on the specific facts and circumstances of an arrangement. Specifically, the Company considers the cost to produce the deliverable, the anticipated margin on that deliverable, the selling price and profit margin for similar parts, its ongoing pricing strategy, the value of any enhancements that have been built into the deliverable, and the characteristics of the varying markets in which the deliverable is sold.
	Revenue recognition involves judgments, including assessments of expected returns and expected customer relationship periods. The Company analyzes various factors, including a review of specific transactions, its historical returns, average customer relationship periods, customer usage, customer balances, and market and economic conditions. Changes in judgments or estimates on these factors could materially impact the timing and amount of revenues and costs recognized. Should market or economic conditions deteriorate, the Company’s actual return or bad debt experience could exceed its estimate.
	Certain product sales are made with a 30-day right of return. Since the Company can reasonably estimate future returns, it recognizes revenues associated with product sales that contain a right of return upon shipment and at the same time it records a sales return reserve, which reduces revenue and accounts receivable by the amount of estimated returns.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable on the balance sheet are recorded net of the allowance for doubtful accounts receivable and the reserve for estimated returns. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company reviews its allowance for doubtful accounts and determines the allowance based on an analysis of customer past payment history, product usage activity, and recent communications between the Company and the customer. Past due balances are reviewed individually for collectibility. Account balances are written-off against the allowance when the Company feels it is probable the receivable will not be recovered. The Company does not have any off-balance sheet credit exposure related to its customers.
Income Taxes	'
	Income Taxes
	The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company’s financial statements contain certain deferred tax assets, which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. In accordance with the provisions of the Income Taxes topic of the Codification, the Company is required to establish a valuation allowance if the likelihood of realization of the deferred tax assets is reduced based on an evaluation of objective verifiable evidence. Significant management judgment is required in determining the Company’s provision for income taxes, the Company’s deferred tax assets and liabilities and any valuation allowance recorded against those net deferred tax assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized.
	Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as well as similar state provisions. Ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.
	If the Company has experienced a change of control, utilization of its NOL or tax credits carryforwards would be subject to an annual limitation under Section 382. Any limitation may result in expiration of a portion of the NOL or research and development credit carryforwards before utilization. Subsequent ownership changes could further impact the limitation in future years. Further, until a study is completed and any limitation known, no amounts are being presented as an uncertain tax position.
	A full valuation allowance has been provided against the Company’s NOL carryforwards and research and development credit carryforwards and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required.
	Management performed a two-step evaluation of all tax positions, ensuring that these tax return positions meet the “more likely than not” recognition threshold and can be measured with sufficient precision to determine the benefit recognized in the financial statements. These evaluations provide management with a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements certain tax positions that the Company has taken or expects to take on income tax returns.
Research and Development	'
	Research and Development
	Costs incurred in the research and development of the Company’s products are expensed as incurred. Included in research and development costs are wages, benefits, product design consulting, and other operating costs such as facilities, supplies, and overhead directly related to the Company’s research and development efforts.
Product Warranty Costs	'
	Product Warranty Costs
	The Company accrues estimated product warranty costs at the time of sale which are included in cost of sales in the statements of operations. The amount of the accrued warranty liability is based on historical information such as past experience, product failure rates, number of units repaired, and estimated cost of material and labor. The liabilities for product warranty costs of $4,719 and $18,629 at December 31, 2013 and 2012, respectively, are included in accrued expenses in the accompanying balance sheets.
Fixed Assets and Long-Lived Assets	'
	Fixed Assets and Long-Lived Assets
	Fixed assets are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Expenditures for repairs and maintenance are charged to expense as incurred. On disposal, the related assets and accumulated depreciation are eliminated from the accounts and any resulting gain or loss is included in the Company’s statement of operations. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvement or the remaining term of the lease.
	The Company periodically evaluates the recoverability of its fixed assets and other long-lived assets whenever events or changes in circumstances indicate that an event of impairment may have occurred. This periodic review may result in an adjustment of estimated depreciable lives or asset impairment. When indicators of impairment are present, the carrying values of the asset are evaluated in relation to the assets operating performance and future undiscounted cash flows of the underlying assets. If the future undiscounted cash flows are less than their book value, an impairment may exist. The impairment is measured as the difference between the book value and the fair value of the underlying asset. Fair values are based on estimates of the market prices and assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates, reflecting varying degrees of perceived risk.
Accounting for Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is generally recognized ratably over the requisite service period. The Company uses the Black-Scholes option pricing model for determining the fair value of its stock options and amortizes its stock-based compensation expense using the straight-line method. The Black-Scholes model requires certain assumptions that involve judgment. Such assumptions are the expected share price volatility, expected life of options, expected annual dividend yield, and risk-free interest rate (See Note 3 — Stock-Based Compensation and Stockholders’ Equity).
Net Loss per Common Share	'
	Net Loss per Common Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic net income per share. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period plus the dilutive effect of the weighted average number of outstanding instruments such as options, warrants, restricted stock, and preferred stock. Because the Company has reported a net loss for all periods presented, diluted loss per common share is the same as basic loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, in calculating net loss per share amounts, shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:
		Years Ended December 31,
		2013		2012		2011
	Options		161,391		53,999		91,411
	Warrants		2,055,733		741,546		238,413
	Unvested restricted stock		22,387		31,699		4,725
	Total		2,239,511		827,244		334,549
	The Beneficial Conversion Feature, or BCF, recorded in the 2013 Offering has been recognized as a deemed dividend attributable to the Preferred Stock and is reflected as an adjustment in the calculation of earnings per share. See Note 14, Stockholders’ Equity, for further details.
	Net loss per common share applicable to common stockholders, basic and diluted was determined as follows:
		Years Ended December 31,
		2013		2012		2011
	Net loss	$	-8,019,137	$	-10,007,553	$	-9,981,105
	Deemed dividend attributable to preferred stockholders in		-766,872		—		—
	connection with beneficial conversion features
	Net loss applicable to common stockholders	$	-8,786,009	$	-10,007,553	$	-9,981,105
	Net loss per common share applicable to common	$	-3.07	$	-5.22	$	-15.53
	stockholders, basic and diluted
	Weighted average number of common shares outstanding,		2,862,094		1,918,723		642,513
	basic and diluted
Advertising and Promotional Costs	'
	Advertising and Promotional Costs
	Advertising and promotional costs are expensed as incurred. Advertising and promotion expense was $151,000, $242,000, and $426,000 in the years ended December 31, 2013, 2012, and 2011, respectively.
Accumulated Other Comprehensive Items	'
	Accumulated Other Comprehensive Items
	For the years ended December 31, 2013, 2012, and 2011, the Company had no components of other comprehensive income or loss other than net loss.
Segments	'
	Segments
	The Company operates in one segment for the sale of medical equipment and consumables. Substantially all of the Company’s assets, revenues, and expenses for the years ended December 31, 2013, 2012, and 2011 were located at or derived from operations in the United States. Revenues from sales outside the United States accounted for approximately 16% of total revenues in 2013, 7% of total revenues in 2012, and 6% of total revenues in 2011.
Risks and Uncertainties	'
	Risks and Uncertainties
	The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, customers’ reimbursement from third-party payers, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.
	In late 2011, the Company launched NC-stat DPNCheck, which is a fast, accurate, and quantitative nerve conduction test for the assessment of systemic neuropathies such as DPN. In early 2013 the Company launched SENSUS for the treatment intractable pain, including pain associated with diabetic neuropathy. The future prospects of the Company are closely tied to its success with NC-stat DPNCheck and SENSUS in market acceptance and growth in future revenues.
Recently Issued or Adopted Accounting Pronouncements	'
	Recently Issued or Adopted Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements since the recent accounting pronouncements described in the Company's 2012 Form 10-K that are of significance to the Company.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of antidilutive securities excluded from computation of earnings per share	'
	the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:
		Years Ended December 31,
		2013		2012		2011
	Options		161,391		53,999		91,411
	Warrants		2,055,733		741,546		238,413
	Unvested restricted stock		22,387		31,699		4,725
	Total		2,239,511		827,244		334,549
Determination of net loss per common share	'
	Net loss per common share applicable to common stockholders, basic and diluted was determined as follows:
		Years Ended December 31,
		2013		2012		2011
	Net loss	$	-8,019,137	$	-10,007,553	$	-9,981,105
	Deemed dividend attributable to preferred stockholders in		-766,872		—		—
	connection with beneficial conversion features
	Net loss applicable to common stockholders	$	-8,786,009	$	-10,007,553	$	-9,981,105
	Net loss per common share applicable to common	$	-3.07	$	-5.22	$	-15.53
	stockholders, basic and diluted
	Weighted average number of common shares outstanding,		2,862,094		1,918,723		642,513
	basic and diluted

StockBased_Compensation_and_St1

Stock-Based Compensation and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation [Abstract]	'
Weighted Average Grant-Date Fair Value Used in the Calculation of Stock-Based Compensation Expense	'
	The weighted average grant-date fair value of stock options used in the calculation of stock-based compensation expense in the accompanying statement of operations for the years ended December 31, 2013, 2012, and 2011 is calculated using the following assumptions:
		Years Ended December 31,
		2013			2012			2011
	Risk-free interest rate		1.4 – 1.7%			0.6% – 0.9%			0.9% – 2.3%
	Expected dividend yield		—			—			—
	Expected option term		5 years			5 years			5 – 6 years
	Volatility		70.00%			70.00%			70.00%
Summary of Option Activity	'
	A summary of option activity for the year ended December 31, 2013 is presented below:
			Number of			Weighted Average			Weighted Average Remaining		Aggregate
			Options			Exercise Price			Contractual Life (in years)		Intrinsic
											Value
	Outstanding at December 31, 2012			51,550		$	73.38
	Granted			265,000			1.76
	Exercised			—			—
	Forfeited			-5,945			19.89
	Expired			-459			81
	Outstanding at December 31, 2013			310,146			13.2			9.02	$	306,925
	Vested or expected to vest at			285,291			14.2			8.96		278,018
	December 31, 2013
	Exercisable at December 31, 2013			41,620			85.01			5.59		—
Summary of Restricted Stock Activity	'
	A summary of restricted stock activity for the year ended December 31, 2013 is presented below:
			Restricted Shares			Weighted
						Average
						Grant Date
						Fair Value
	Restricted shares at December 31, 2012			38,272		$	5.25
	Granted			2,000			1.9
	Vested			-19,421			-5.66
	Canceled			-3,375			-4.2
	Restricted shares at December 31, 2013			17,476		$	4.62
Reserved Authorized Shares of Common Stock for Future Issuance	'
	At December 31, 2013, the Company has reserved authorized shares of common stock for future issuance as follows:
	Warrants			1,839,278
	Outstanding stock options			310,146
	Possible future issuance under inducement plan			400,000
	Possible future issuance under stock option plans			97,440
	Possible future issuance under employee stock purchase plan			22,338
	Total			2,669,202

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories consist of the following:
		December 31,
		2013		2012
	Purchased components	$	205,320	$	187,567
	Finished goods		357,716		646,959
		$	563,036	$	834,526

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Fixed Assets	'
	Fixed assets consist of the following:
				December 31,
			Estimated Useful Life (Years)	2013		2012
	Computer and laboratory equipment		3	$	1,748,566	$	2,689,519
	Furniture and equipment		3		249,377		644,034
	Production equipment		7		997,297		997,297
	Leasehold improvements		*		185,255		179,997
					3,180,495		4,510,847
	Less – accumulated depreciation				-2,951,182		-4,216,950
				$	229,313	$	293,897
		*	Lesser of life of lease or estimated useful life.

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following for the years ended December 31, 2013 and 2012:
		December 31,
		2013		2012
	Technology fees	$	450,000	$	450,000
	Professional services		263,642		248,759
	Clinical study obligations		51,424		24,490
	Sales taxes		32,688		62,385
	Supplier obligations		—		105,132
	Other		72,442		58,077
		$	870,196	$	948,843

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Current Income Tax Expense Benefit Attributable to Continuing Operations	'
	Current income tax expense (benefit) attributable to continuing operations consists of the following for the years ended December 31, 2013, 2012, and 2011.
		Years Ended December 31,
		2013		2012		2011
	Federal		—		—		—
	State		—		—		—
	Total		—		—		—
Effective Income Tax Rate Differs from the Statutory Federal Income Tax Rate	'
	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended December 31, 2013, 2012, and 2011.
		Years Ended December 31,
		2013		2012		2011
	Federal tax provision (benefit) rate	-34	%	-34	%	-34	%
	State tax provision, net of federal provision	-4.8		-3.5		-3.4
	Permanent items	3.4		0.8		1.9
	Federal research and development credits	-1.7		—		-0.5
	Valuation allowance	37.1		36.7		36
	Effective income tax rate	—	%	—	%	—	%
Deferred Tax Assets	'
	The Company’s deferred tax assets consist of the following:
		December 31,
		2013		2012
	Deferred tax assets:
	Net operating loss carryforwards	$	32,253,602	$	30,514,469
	Research and development credit carryforwards		1,735,265		1,547,374
	Accrued expenses		493,075		643,952
	Stock-based compensation		565,077		593,131
	Other		1,061,212		1,048,541
	Total gross deferred tax assets		36,108,231		34,347,467
	Valuation allowance		-36,108,231		-34,347,467
	Net deferred tax assets	$	—	$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments Under Noncancelable Operating Leases	'
	Future minimum lease payments under noncancelable operating leases as of December 31, 2013 are as follows:
	2014	$	635,004
	2015		158,751
	Total minimum lease payments	$	793,755
Future Minimum Lease Payments Under the Capital Lease	'
	Future minimum lease payments under the capital lease as of December 31, 2012 were as follows:
	2013	$	18,446
	Total minimum lease payments		18,446
	Less: Amount representing imputed interest		517
	Present value of future minimum lease payments	$	17,929

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
					Fair Value Measurements at December 31, 2013 Using
		December 31,			Quoted Prices in Active Markets		Significant		Significant Unobservable
		2013			for Identical Assets		Other Observable		Inputs (Level 3)
					(Level 1)		Inputs
							(Level 2)
	Assets:
	Cash equivalents	$	3,926,600		$	3,926,600	$	—	$	—
	Total	$	3,926,600		$	3,926,600	$	—	$	—
	Liabilities:
	Common stock warrants	$	1,938,603		$	—	$	—		1,938,603
	Total	$	1,938,603		$	—	$	—	$	1,938,603
				Fair Value Measurements at December 31, 2012 Using
		December 31,			Quoted Prices in Active Markets		Significant		Significant Unobservable
		2012			for Identical Assets		Other Observable		Inputs (Level 3)
					(Level 1)		Inputs
							(Level 2)
	Assets:
	Cash equivalents	$	519,242		$	519,242	$	—	$	—
	Total	$	519,242		$	519,242	$	—	$	—
Fair Value, Liabilities Measured on Recurring Basis	'
	The following table provides a summary of changes in the fair value of the Company's Level 3 financial liabilities for the year ended December 31, 2013:
	Balance at December 31, 2012	$	—
	Initial fair value of warrants at issuance in June 2013		4,011,205
	Change in fair value of warrant liability		289,657
	Reclassification of liability to additional paid-in capital upon exercise of warrants		-2,362,259
	Balance at December 31, 2013	$	1,938,603

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)	1 Months Ended			12 Months Ended				1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 04, 2013	Mar. 31, 2012	Feb. 13, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jun. 04, 2013	Jun. 04, 2013	Dec. 31, 2013	Dec. 31, 2013
								Series A One Convertible Preferred Stock	Series A Two Convertible Preferred Stock	Series A Preferred Stock	Series A Preferred Stock
Organization And Basis Of Presentation [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Stock issued during period, shares, other	248,147	23,127	'	'	'	'	'	1,066.25	3,370.51	'	2,117,787
Share price	$2.10	'	'	$2.92	'	'	'	$1,000	$1,000	'	'
Exercise price of warrants or rights	2	'	'	'	'	'	'	'	'	'	'
Class Of Warrant Or Right Exercisable Period	'5 years	'	'5 years	'	'	'	'	'	'5 years	'	'
Gross proceeds from issuance or sale of equity	$5,000,000	'	'	'	'	'	'	'	'	'	'
Proceeds from issuance or sale of equity	4,500,000	'	7,400,000	7,155,191	7,482,884	33,614	'	'	'	'	'
Cash and cash equivalents	'	'	'	9,195,753	8,699,478	10,290,446	16,986,809	'	'	'	'
Shares of common stock issuable upon exercise of warrants	2,365,934	'	'	'	'	'	'	'	'	1,308,611	'
Convertible preferred stock, shares issued upon conversion	477.327	'	'	'	'	'	'	'	'	'	'
Proceeds from stock options exercised	2,600,000	'	'	'	'	'	'	'	'	'	'
Class of stock warrants exercised	'	'	'	'	'	'	'	'	'	$1,308,611	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Liabilities for product warranty costs	$4,719	$18,629	'
Advertising and promotional costs	$151,000	$242,000	$426,000
Percentage of revenues from sales outside the United States	16.00%	7.00%	6.00%
Accounts Receivable | Customer One	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Concentration risk, percentage	14.00%	'	'
Accounts Receivable | Customer Two	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'
Concentration risk, percentage	12.00%	'	'

Antidilutive_Common_Stock_Equi

Anti-dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Income Per Common Share (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Potentially dilutive common stock equivalents excluded from calculation of diluted net income per common share	2,239,511	827,244	334,549
Options	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Potentially dilutive common stock equivalents excluded from calculation of diluted net income per common share	161,391	53,999	91,411
Warrants	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Potentially dilutive common stock equivalents excluded from calculation of diluted net income per common share	2,055,733	741,546	238,413
Unvested Restricted Stock	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Potentially dilutive common stock equivalents excluded from calculation of diluted net income per common share	22,387	31,699	4,725

Determination_of_net_loss_per_

Determination of net loss per common share (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Determination of net loss per common share [Line Items]	'	'	'
Net loss	($8,019,137)	($10,007,553)	($9,981,105)
Deemed dividend attributable to preferred stockholders in connection with beneficial conversion features	-766,872	0	0
Net loss applicable to common stockholders	($8,786,009)	($10,007,553)	($9,981,105)
Net loss per common share applicable to common stockholders, basic and diluted	($3.07)	($5.22)	($15.53)
Weighted average number of common shares outstanding, basic and diluted	2,862,094	1,918,723	642,513

StockBased_Compensation_and_St2

Stock-Based Compensation and Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

6-May-13

Jun. 04, 2013

Mar. 31, 2013

Mar. 31, 2012

Feb. 13, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 04, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2004

Dec. 31, 2004

Dec. 31, 2013

Dec. 31, 2004

Dec. 31, 2013

Jun. 30, 2004

14-May-12

31-May-10

Dec. 31, 2013

Dec. 31, 2012

Jun. 04, 2013

Jun. 04, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Non-employees

Non-employees

Non-employees

Minimum

Minimum

Maximum

2004 Stock Plan

2004 Stock Plan

2009 Inducement Plan

2004 Employee Stock Purchase Plan

2010 Employee Stock Purchase Plan

2010 Employee Stock Purchase Plan

2010 Employee Stock Purchase Plan

2010 Employee Stock Purchase Plan

Series A One Convertible Preferred Stock [Member]

Series A Two Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A One and Two Convertible Preferred Stock

Stock Based Compensation And Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of the Company's common stock authorized for issuance

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Plan generally terminate after the grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Common stock were authorized for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

576,279

'

400,000

10,417

'

6,945

'

'

'

'

'

'

'

Shares Issued in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

128,644

'

'

'

'

'

16,094

8,895

'

'

'

'

'

Shares subject to outstanding options

'

'

'

'

'

310,146

51,550

'

'

'

'

'

'

'

'

309,046

'

'

'

'

'

22,338

'

'

'

'

'

'

Weighted average exercise price

'

'

'

'

'

$13.20

$73.38

'

'

'

'

'

'

'

'

$12.37

'

'

'

'

'

'

'

'

'

'

'

'

Shares were available for future grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

97,440

'

'

'

'

'

'

'

'

'

'

'

'

Holders of more than total combined voting power of all classes of stock

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incentive stock options may not be granted at less than fair market value

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'All of the Company’s employees who had been employed by the Company for at least 60 days and whose customary employment is for more than 20 hours per week and for more than five months in any calendar year were eligible to participate and any employee who owned 5% or more of the voting power or value of the Company’s stock was not eligible to participate.

'

'equal to the lesser of (i) 6,945 shares, (ii) 1 percent of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares as is determined by the Board. At the Company’s Annual Meeting of Stockholders held on May 14, 2012, the stockholders of the Company approved the Company’s Amended and Restated 2010 Employee Stock Purchase Plan (the “Amended and Restated 2010 ESPP”), which, among other things, increased the number of shares of the Company’s common stock authorized for issuance thereunder by 16,667 shares. All of the Company’s full-time employees and certain part-time employees are eligible to participate in the Amended and Restated 2010 ESPP. For part-time employees to be eligible, they must have customary employment of more than five months in any calendar year and more than 20 hours per week. Employees who, after exercising their rights to purchase shares under the Amended and Restated 2010 ESPP, would own shares representing 5% or more of the voting power of the Company’s common stock, are ineligible to participate.

'

'

'

'

'

'

'

Participating employees can authorize to percentage of withholdup earnings during consecutive six-month payment periods for the purchase of the shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

Weighted average per share grant-date fair values of options granted

'

'

'

'

'

$1.02

$2.67

$11.34

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options issued or exercised

'

'

'

'

'

$0

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized stock-based compensation costs related to non-vested stock options

'

'

'

'

'

$247,468

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized stock-based compensation costs related to non-vested stock options related to, number of shares

'

'

'

'

'

286,022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized stock-based compensation costs related to non-vested stock options related to, per share weighted fair value

'

'

'

'

'

$0.87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized cost is expected to be recognized over a weighted average period of approximately

'

'

'

'

'

'4 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of restricted stock have been granted to employee

'

'

'

'

'

2,000

37,167

3,630

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of stock withholding with company by employee, in lieu of paying withholding taxes on the vesting of restricted stock

'

'

'

'

'

4,214

721

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash received from option exercises and purchases

'

'

'

'

'

26,000

23,000

34,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

246,000

319,000

837,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, shares, other

'

248,147

'

23,127

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,066.25

3,370.51

'

2,117,787

2,117,787

Share price

'

$2.10

'

'

'

$2.92

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

'

'

'

Preferred stock, stated value

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

'

'

'

Class of warrant or right, Number of securities called by warrants or rights

'

2,365,934

'

'

781,955

2,365,934

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, Exercise price of warrants or rights

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of stock warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,308,611

'

'

Proceeds from Stock Options Exercised

'

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

119,370

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Bonuses

'

'

285,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing Price Of Shares

'

'

'

'

'

'

'

'

$2.39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public Offering Units

'

'

'

'

1,421,735

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unit Issued During Period Price Per Unit New Issues

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price Of Warrants

'

'

'

'

6.9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period Shares Public Offering

'

'

'

'

1,421,735

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance or Sale of Equity, Total

'

$4,500,000

'

'

$7,400,000

$7,155,191

$7,482,884

$33,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

'

'

'

'

5,945,581

2,140,871

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Common stock authorized

'

'

'

'

'

50,000,000

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding

'

'

'

'

'

5,945,581

2,140,871

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Maximum Term Of Grant Of Common Stock

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Shares Outstanding

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

265,000

'

'

'

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of stock warrants exercise period

'

'five year warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Per Unit Of Common Stock Description

'

'

'

'

'one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted_Average_GrantDate_Fai

Weighted Average Grant-Date Fair Value Used in the Calculation of Stock-Based Compensation Expense (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Expected dividend yield	0.00%	0.00%	0.00%
Expected option term	'5 years	'5 years	'
Volatility	70.00%	70.00%	70.00%
Maximum	'	'	'
Risk-free interest rate	1.70%	0.90%	2.30%
Expected option term	'	'	'6 years
Minimum	'	'	'
Risk-free interest rate	1.40%	0.60%	0.90%
Expected option term	'	'	'5 years

Summary_of_option_activity_Det

Summary of option activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Summary Of Option Activity [Line Items]	'
Number of Options Outstanding at December 31, 2012	51,550
Number of Options, Granted	265,000
Number of Options, Exercised	0
Number of Options, Forfeited	-5,945
Number of Options, Expired	-459
Number of Options Outstanding at December 31, 2013	310,146
Number of Options, Vested or expected to vest at December 31, 2013	285,291
Number of Options, Exercisable at December 31, 2013	41,620
Weighted Average Exercise Price Outstanding at December 31, 2012	$73.38
Weighted Average Exercise Price, Granted	$1.76
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price , Forfeited	$19.89
Weighted Average Exercise Price, Expired	$81
Weighted Average Exercise Price Outstanding at December 31, 2013	$13.20
Weighted Average Exercise Price, Vested or expected to vest at December 31, 2013	$14.20
Weighted Average Exercise Price, Exercisable at December 31, 2013	$85.01
Weighted Average Remaining Contractual Life (in years), Outstanding at December 31, 2013	'9 years 7 days
Weighted Average Remaining Contractual Life (in years), Vested or expected to vest at December 31, 2013	'8 years 11 months 16 days
Weighted Average Remaining Contractual Life (in years), Exercisable at December 31, 2013	'5 years 7 months 2 days
Aggregate Intrinsic Value, Outstanding at December 31, 2013	$306,925
Aggregate Intrinsic Value, Vested or expected to vest at December 31, 2013	278,018
Aggregate Intrinsic Value, Exercisable at December 31, 2013	$0

Summary_of_restricted_stock_ac

Summary of restricted stock activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Summary Of Restricted Stock Activity [Line Items]	'
Restricted shares at December 31, 2012	38,272
Restricted Shares, Granted	2,000
Restricted Shares, Vested	-19,421
Restricted Shares, Canceled	-3,375
Restricted shares at December 31, 2013	17,476
Weighted Average Grant Date Fair Value Restricted shares at December 31, 2012	$5.25
Weighted Average Grant Date Fair Value Restricted Shares, Granted	$1.90
Weighted Average Grant Date Fair Value Restricted Shares, Vested	($5.66)
Weighted Average Grant Date Fair Value Restricted Shares, Canceled	($4.20)
Weighted Average Grant Date Fair Value Restricted shares at December 31, 2013	$4.62

Company_has_reserved_authorize

Company has reserved authorized shares of common stock for future issuance (Detail)	Dec. 31, 2013
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	2,669,202
Outstanding stock options	'
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	310,146
Possible future issuance under inducement plan	'
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	400,000
Possible future issuance under stock option plans	'
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	97,440
Possible future issuance under employee stock purchase plan	'
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	22,338
Warrants	'
Future Issuance Of Common Stock [Line Items]	'
Common stock capital shares reserved for future issuance	1,839,278

Intangible_Assets_Additional_i

Intangible Assets - Additional information (Detail) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2009	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Acquired technological and intellectual property assets	$350,000	'	'	'	'	'
Estimated life intangible Assets	'5 years	'	'	'	'	'
Amortization expense of technological, intellectual property	'	'	17,500	0	0	'
Intangible asset impairment	'	$192,500	'	$0	$0	$192,500

Inventories_Detail

Inventories (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Line Items]	'	'
Purchased components	$205,320	$187,567
Finished goods	357,716	646,959
Inventories	$563,036	$834,526

Fixed_Assets_Detail

Fixed Assets (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Fixed Assets [Line Items]	'		'
Fixed assets, gross	$3,180,495		$4,510,847
Less - accumulated depreciation	-2,951,182		-4,216,950
Fixed assets, net	229,313		293,897
Computer and laboratory equipment	'		'
Fixed Assets [Line Items]	'		'
Fixed assets, estimated useful life	'3 years		'
Fixed assets, gross	1,748,566		2,689,519
Furniture and equipment	'		'
Fixed Assets [Line Items]	'		'
Fixed assets, estimated useful life	'3 years		'
Fixed assets, gross	249,377		644,034
Production equipment	'		'
Fixed Assets [Line Items]	'		'
Fixed assets, estimated useful life	'7 years		'
Fixed assets, gross	997,297		997,297
Leasehold improvements	'		'
Fixed Assets [Line Items]	'		'
Fixed assets, estimated useful life	'	[1]	'
Fixed assets, gross	$185,255		$179,997
[1]	Lesser of life of lease or estimated useful life.

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Depreciation expense	$150,663	$239,168	$359,432

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Schedule of Accrued Liabilities [Line Items]	'	'
Technology fees	$450,000	$450,000
Professional services	263,642	248,759
Clinical study obligations	51,424	24,490
Sales taxes	32,688	62,385
Supplier obligations	0	105,132
Other	72,442	58,077
Accrued expenses	$870,196	$948,843

Restructuring_Related_Activity1

Restructuring Related Activity - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2011	Dec. 31, 2011	Dec. 31, 2010
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring and related cost number of positions eliminated	25	'	'
Restructuring and related cost expected cost	$2.20	'	'
Restructuring charges	'	'	2
Accrual for severance	'	0.2	0.2
Inventories were reduced by charges related to the business restructuring	'	'	$1.80

Current_income_tax_expense_ben

Current income tax expense benefit attributable to continuing operations (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Federal	$0	$0	$0
State	0	0	0
Total	$0	$0	$0

Company_effective_income_tax_r

Company effective income tax rate differs from the statutory federal income tax rate (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Federal tax provision (benefit) rate	-34.00%	-34.00%	-34.00%
State tax provision, net of federal provision	-4.80%	-3.50%	-3.40%
Permanent items	3.40%	0.80%	1.90%
Federal research and development credits	-1.70%	0.00%	-0.50%
Valuation allowance	37.10%	36.70%	36.00%
Effective income tax rate	0.00%	0.00%	0.00%

Company_deferred_tax_assets_De

Company deferred tax assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$32,253,602	$30,514,469
Research and development credit carryforwards	1,735,265	1,547,374
Accrued expenses	493,075	643,952
Stock-based compensation	565,077	593,131
Other	1,061,212	1,048,541
Total gross deferred tax assets	36,108,231	34,347,467
Valuation allowance	-36,108,231	-34,347,467
Net deferred tax assets	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Federal	State and local jurisdiction	Federal And State Research And Development Credits
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Operating loss carry forwards	'	'	$97,100,000	$18,600,000	'
Tax credit carry forward amount	'	'	1,100,000	977,000	'
Amount includes tax benefits	3,900,000	'	'	'	'
Income tax expense benefit attributable to tax credit carry forwards	71,000	'	'	'	'
Valuation allowance amount	$36,108,231	$34,347,467	'	'	'
Operating loss carryforwards, expiration dates	'	'	'Begin to expire in 2019	'Begin to expire in 2014	'Begin to expire in 2018

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	Jun. 30, 2013	Oct. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'
Lease expiration date	31-Mar-15	'	'	'	'
Base rent, per month	'	'	$52,917	'	'
Operating Leases, Rent Expense	'	'	635,004	709,164	764,754
Capital Lease Obligations Incurred	'	60,410	'	'	'
Purchase Obligation, Total	'	'	$147,806	'	'

Future_minimum_lease_payments_

Future minimum lease payments under noncancelable operating leases (Detail) (USD $)	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
2014	$635,004
2015	158,751
Total minimum lease payments	$793,755

Future_minimum_lease_payments_1

Future minimum lease payments under the capital lease (Detail) (USD $)	Dec. 31, 2012
Capital Leased Assets [Line Items]	'
2013	$18,446
Total minimum lease payments	18,446
Less: Amount representing imputed interest	517
Present value of future minimum lease payments	$17,929

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Feb. 13, 2012	Dec. 31, 2013	Jun. 04, 2013
Fair Value Disclosures [Line Items]	'	'	'
Share price	'	$2.92	$2.10
Exercise price	'	$2	'
Risk free interest rate	0.85%	1.71%	'
Expected term	'5 years	'5 years	'
Expected volatility	73.50%	67.60%	'
Common stock warrants liability	'	$1,938,603	'
Transfer of liability to additional paid-in capital upon exercise of warrants	'	$2,362,259	'
Class of class stock warrants or rights exercised	'	1.3	'

Assets_and_Liabilities_Measure

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Assets:	'	'
Cash equivalents	$3,926,600	$519,242
Total	3,926,600	519,242
Liabilities:	'	'
Common stock warrants	1,938,603	'
Total	1,938,603	'
Fair Value, Inputs, Level 1	'	'
Assets:	'	'
Total	3,926,600	519,242
Liabilities:	'	'
Total	0	'
Fair Value, Inputs, Level 1 | Fair Value, Measurements, Recurring	'	'
Assets:	'	'
Cash equivalents	3,926,600	519,242
Liabilities:	'	'
Common stock warrants	0	'
Fair Value, Inputs, Level 2	'	'
Assets:	'	'
Total	0	0
Liabilities:	'	'
Total	0	'
Fair Value, Inputs, Level 2 | Fair Value, Measurements, Recurring	'	'
Assets:	'	'
Cash equivalents	0	0
Liabilities:	'	'
Common stock warrants	0	'
Fair Value, Inputs, Level 3	'	'
Assets:	'	'
Total	0	0
Liabilities:	'	'
Total	1,938,603	'
Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring	'	'
Assets:	'	'
Cash equivalents	0	0
Liabilities:	'	'
Common stock warrants	$1,938,603	'

Summary_of_changes_in_fair_val

Summary of changes in fair value of company's level 3 financial liabilities (Details) (Warrants, USD $)	12 Months Ended
	Dec. 31, 2013
Warrants	'
Summary of changes in the fair value [Line Items]	'
Balance at December 31, 2012	$0
Initial fair value of warrants at issuance in June 2013	4,011,205
Change in fair value of warrant liability	289,657
Reclassification of liability to additional paid-in capital upon exercise of warrants	-2,362,259
Balance at December 31, 2013	$1,938,603

Credit_Facility_Additional_Inf

Credit Facility - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Line of Credit Facility [Line Items]	'
Revolving credit facility, maximum borrowing capacity	$2,500,000
Credit Facility expiration date	15-Jan-15
Credit Facility limit restricted to support letter of credit	225,000
Line of credit facility, remaining borrowing capacity	2,275,000
Line of Credit Facility, Maximum Borrowing Capacity in case of Not Compliance with Agreement	750,000
Prime Rate	'
Line of Credit Facility [Line Items]	'
Interest rate over prime rate	0.50%
31-Dec-14	'
Line of Credit Facility [Line Items]	'
Line of credit facility, remaining borrowing capacity	$2,500,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

Jun. 04, 2013

Mar. 31, 2012

Feb. 13, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 01, 2011

Feb. 15, 2013

Jul. 26, 2013

Jun. 03, 2009

Jun. 04, 2013

Jun. 04, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 13, 2012

Feb. 13, 2012

Feb. 13, 2012

First Stock Split

Second Stock Split

2009 Stock Plan

2009 Stock Plan

Series A One Convertible Preferred Stock

Series A Two Convertible Preferred Stock

Series A One and Two Convertible Preferred Stock

Warrants

Placement Agent

Public Offering

Minimum

Public Offering

Public Offering Of Common Stock and Warrants [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering of units

'

'

1,421,735

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering of units, price per unit

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering of units, description

'

'

'Each Unit consists of one share of the Companys common stock and one warrant to purchase one half of a share of the Companys common stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued in public offering

'

'

1,421,735

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issuable upon exercise of warrants

2,365,934

'

'

'

'

'

'

'

'

'

'

'

'

'

71,087

710,868

'

Net proceed from offering common stock and warrants

$4,500,000

'

$7,400,000

$7,155,191

$7,482,884

$33,614

'

'

'

'

'

'

'

'

'

'

'

Period over which warrants become exercisable

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'180 days

Warrant exercise price

'

'

6.9

'

'

'

'

'

'

'

'

'

'

'

7.5

6.9

'

Warrant exercise price Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125.00%

115.00%

'

Common stock warrants issued to placement agent as a percentage of total units sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

Fair Value of Warrants

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

Exercise price

'

'

'

$2

'

'

'

'

'

'

'

'

'

$2

'

'

'

Expected volatility

'

'

73.50%

67.60%

'

'

'

'

'

'

'

'

'

73.60%

'

'

'

Risk free interest rate

'

'

0.85%

1.71%

'

'

'

'

'

'

'

'

'

1.05%

'

'

'

Expected life

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Stock issued during period, shares, other

248,147

23,127

'

'

'

'

'

'

'

'

1,066.25

3,370.51

2,117,787

'

'

'

'

Share price

$2.10

'

'

$2.92

'

'

'

'

'

'

$1,000

$1,000

'

$2.60

'

'

'

Preferred stock, stated value

'

'

'

$1,000

'

'

'

'

'

'

$1,000

$1,000

'

'

'

'

'

Gross proceeds from issuance or sale of equity

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, Discount on shares

'

'

'

766,900

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, Number of securities called by warrants or rights

2,365,934

'

781,955

2,365,934

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, Exercise price of warrants or rights

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, issued

'

'

'

5,945,581

2,140,871

'

'

'

386,111

13,889

'

'

'

'

'

'

'

Stockholders equity note reverse stock split conversion ratio

'

'

'

'

'

'

'1-for-6

'1-for-6

'

'

'

'

'

'

'

'

'

Non-Operating Expense

'

'

'

290,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, Convertible, Conversion price

'

'

'

$2.10

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of class stock warrants or rights exercised

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

1,308,611

'

'

'

Proceeds from stock options exercised

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants liability

'

'

'

$1,938,603

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse_Stock_Split_Additional

Reverse Stock Split - Additional Information (Detail)	1 Months Ended		0 Months Ended
	Sep. 01, 2011	Dec. 31, 2013	Feb. 15, 2013	Dec. 31, 2013
	First Stock Split	First Stock Split	Second Stock Split	Second Stock Split
Stockholders equity note reverse stock split conversion ratio	'1-for-6	'	'1-for-6	'
Common stock outstanding, immediately prior to reverse stock split	23,331,646	'	12,845,228	'
Common stock outstanding, as a result of reverse stock split	'	3,888,607	'	2,140,871

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Allowance for Doubtful Accounts	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Balance at Beginning of Period	$130,000		$286,612		$379,100
Charged to costs and expenses	111,296		-12,999		30,825
Charged to other accounts	0		0		0
Recoveries/ (Deductions)	-206,296		-143,613	[1]	-123,313	[1]
Balance at End of Period	35,000		130,000		286,612
Sales Returns Reserve	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Balance at Beginning of Period	21,616		13,302		26,865
Charged to costs and expenses	0		0		0
Charged to other accounts	38,278		180,066		272,607
Recoveries/ (Deductions)	-58,999		-171,752	[1]	-286,170	[1]
Balance at End of Period	895		21,616		13,302
Deferred Tax Asset Valuation Allowance	'		'		'
Valuation and Qualifying Accounts Disclosure [Line Items]	'		'		'
Balance at Beginning of Period	34,347,467		30,487,085		28,670,035
Charged to costs and expenses	2,976,809		3,900,388		3,803,223
Charged to other accounts	0		0		0
Recoveries/ (Deductions)	-1,216,045	[2]	-40,006	[2]	-1,986,173	[2]
Balance at End of Period	$36,108,231		$34,347,467		$30,487,085
[1]	Net write-offs.
[2]	Expiration of Federal and State Net Operating Loss Carryforwards and other reductions.